Increased IL6 expression has therefore been proposed as a clinically relevant factor for poor prognosis in patients with a number of cancers, including colorectal cancer, non-small cell lung cancer, Hodgkin’s lymphoma, and renal cell carcinoma [9]–[11], [17]. This evidence concerns the gene IL6 and renal cell carcinoma.